Board of Directors
MAX E. LINK, PH.D.
Chairman of the Board
Director since January 1997
Max E. Link, Ph.D., has served as a director of the Company since 1997 and has been the Chairman of the Board of Directors since October 2001. Dr. Link currently provides consulting and advisory services to a number of pharmaceutical and biotechnology companies. From 1993 to 1994, Dr. Link served as Chief Executive Officer of Corange, Ltd., a life science company that was subsequently acquired by Hoffman-LaRoche. From 1971 to 1993, Dr. Link served in numerous positions with Sandoz Pharma AG, culminating in his appointment as Chairman of the Board of Directors in 1992. From 2001 to 2003, Dr. Link served as Chairman and Chief Executive Officer of Centerpulse, Ltd. Dr. Link currently serves on the Board of Directors of Alexion Pharmaceuticals, Inc., Discovery Laboratories, Inc., and Cytrx Corporation. Dr. Link holds a Ph.D. in economics from the University of St. Gallen (Switzerland).
Michael H. Tardugno
President and Chief Executive Officer
Director since January 2007
Michael Tardugno’s career has been exclusively focused in healthcare, with 30 years of experience in the pharmaceutical and medical device industries. Mr. Tardugno was appointed President and Chief Executive Officer of Celsion on January 3, 2007 and was elected to the Board of Directors on January 22, 2007. Prior to joining the company, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories, where he held positions in pharmaceutical operations. Mr. Tardugno holds a B.S. in Biology from St. Bonaventure University and completed the Harvard Business School executive program.
AUGUSTINE CHOW, M.SC., PH.D.
Director since March 2007
Augustine Chow, M.Sc., Ph.D., was appointed to the Celsion Board of Directors in March 2007. He has served as the Chief Executive Officer of Harmony Asset Limited, a publicly listed investment company specializing in China and Hong Kong, since 1996. He also serves as the Chief Executive Officer of Pacific Life Science Holdings, Ltd. From 1990-1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies, based in Hong Kong. Previously, Dr. Chow held increasingly senior positions with Brunswick Corporation and Outboard Marine Corporation. Dr. Chow has held numerous directorships of listed and non-listed companies, principally in Hong Kong, China, and the UK. He currently serves as an independent director of Medifocus, Inc. He has also participated in and managed over fifty direct investments in China. Dr. Chow holds an M.S. from London Business School, a Ph.D. in Transfer of Technology from the University of South Australia, a D.B.A. in Internet Research from Southern Cross University, and an Engineering Doctorate in Commercialization of Radical Innovation from the City University of Hong Kong.
Robert W. Hooper
Director since August 2010
Robert W. Hooper was appointed to the Board of Directors in August 2010 and currently serves as President of Crows Nest Ventures, Inc., an advisory and consulting services firm to the healthcare industry. From 1997-2001 he served as President, North America for IMS Health, the global leader in healthcare information and market research. From 1993-1997 Mr. Hooper served as President of Abbott Laboratories Canada, based in Montreal. From 1989-1993 he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to 1989 Mr. Hooper served as Director of Manufacturing and Plant Manager for Abbott’s Nutritional and Hospital Products Divisions. Mr. Hooper began his career with E.R. Squibb and Sterling Winthrop Labs. He received a B.A. in Biology from Wilkes University.
ALBERTO MARTINEZ, M.D.
Director since December 2010
Alberto Martinez, M.D., has served as a Director of the Company since December 2010. He is currently a consultant to the healthcare industry. From 2007 to 2008, Dr. Martinez served as the President and Chief Executive Officer of Talecris Biotherapeutics, a publicly traded life science company. Prior to that, he was Executive Vice President of Worldwide Commercial Operations for CSL Behring, the company formed by the 2004 acquisition of Aventis Behring by the Australian company CSL. He was Vice President and General Manager for Emerging Markets for Aventis Behring from 1996-2000 and served as President of Aventis BioServices from 2000-2004. Dr. Martinez began his career with Sandoz Ltd. (known today as Novartis). He spent twenty years working with the Sandoz in a variety of roles across the world, including Director and Head of Corporate Strategic Planning in the United States, Head of the Latin America Business Operations in Switzerland, Director of Marketing and Sales in Spain, and Head of Marketing and Clinical Research in Brazil. Dr. Martinez completed his undergraduate and graduate studies at the University of Sao Paulo and received his medical degree from the University of Sao Paulo in 1973. After completing his residency in Pediatrics in 1975, he studied Business and Marketing Administration at the Fundação Getúlio Vargas in Sao Paulo, Brazil.
Frederick J. Fritz
Director since July 2011
Frederick J. Fritz was appointed to the Board of Directors in July 2011. He is the CEO and Founder of NeuroDx, a development-stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003, to develop the world’s first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device company spin out of Sarnoff Corp. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough’s Wesley Jessen in 1985 as Vice President, Marketing and Sales in 1986. He was promoted to general manager of Schering’s OTC pharmaceutical business in 1988 and of the podiatric products business in 1990. Additionally, Mr. Fritz was President of Coleman North America from 1995-1997. He holds an Engineering degree from the University of Illinois, from which he was graduated Summa Cum Laude, and an M.B.A. from Harvard Business School.